Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 416

1.

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.

Vokó Z, Nagyjánosi L, Kaló Z.

BMC Public Health. 2012 Oct 30;12:924. doi: 10.1186/1471-2458-12-924.

2.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

3.

Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.

Gomez JA, Lepetic A, Demarteau N.

BMC Public Health. 2014 Nov 26;14:1222. doi: 10.1186/1471-2458-14-1222.

4.
5.

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.

Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N.

BMC Public Health. 2009 Oct 31;9:401. doi: 10.1186/1471-2458-9-401.

6.

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G.

Sex Health. 2007 Sep;4(3):165-75.

PMID:
17931529
7.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
8.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
9.

Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.

Obradovic M, Mrhar A, Kos M.

Eur J Public Health. 2010 Aug;20(4):415-21. doi: 10.1093/eurpub/ckp208. Epub 2010 Jul 12.

11.

Cost-effectiveness of human papilloma virus vaccination in Iceland.

Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.

Acta Obstet Gynecol Scand. 2009;88(12):1411-6. doi: 10.3109/00016340903322750.

PMID:
19900074
12.
13.

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.

Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.

J Med Econ. 2010 Mar;13(1):110-8. doi: 10.3111/13696990903546013.

PMID:
20085477
14.

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.

Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.

Int J Technol Assess Health Care. 2008 Winter;24(1):10-9. doi: 10.1017/S0266462307080026.

PMID:
18218164
15.

A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.

Guerrero AM, Genuino AJ, Santillan M, Praditsitthikorn N, Chantarastapornchit V, Teerawattananon Y, Alejandria M, Toral JA.

BMC Public Health. 2015 Jul 30;15:730. doi: 10.1186/s12889-015-2046-1.

16.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.

Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.

BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x. Epub 2011 Apr 12.

17.

Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.

Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.

Value Health. 2012 Jul-Aug;15(5):622-31. doi: 10.1016/j.jval.2012.02.012. Epub 2012 Jun 12.

18.

Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.

Pearson AL, Kvizhinadze G, Wilson N, Smith M, Canfell K, Blakely T.

BMC Infect Dis. 2014 Jun 26;14:351. doi: 10.1186/1471-2334-14-351.

19.

A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.

Dee A, Howell F.

Eur J Public Health. 2010 Apr;20(2):213-9. doi: 10.1093/eurpub/ckp141. Epub 2009 Oct 28.

20.

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.

J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk